Tag Archives: 3D cell culture

  • 0

3 Posters @ AACR 2017 in DC

Tags : 

Three KIYATEC abstracts accepted for poster presentations during 2017 AACR Conference in Washington D.C.

KIYATEC, a private company prioritizing accurate ex vivo prediction of patients’ response to drug treatment, received acceptance of three posters for presentations during the upcoming AACR conference.

GREENVILLE, SC, March 21, 2017– KIYATEC Inc. is pleased to announce that three abstracts have been accepted by the committee at the American Association for Cancer Research (www.aacr.org).  KIYATEC scientific and business development staff will be in attendance at the conference.  In addition to the poster presentations, also KIYATEC will be exhibiting at Booth 1556.  Stop by to learn more about our 10+ years of 3D cell culture experience and the latest 3D co-culture model development projects focused on immuno-oncology applications.

  •  Abstract #1923 / 24 – Paired isolation and expansion of CSC and CTC from primary small cell lung cancer patient tissue and blood using the 3DKUBE bioreactor platform | Monday Apr 3, 2017 8:00 AM – 12:00 PM | Location: Section 41 / Poster 24 (LINK)
  • Abstract #4834 / 24 – 3D modeling of immune cell interactions in breast cancer and prediction of immunotherapy response | Tuesday,
    Apr 4, 2017, 1:00 PM – 5:00 PMLocation: Section 39 / Poster 24 (LINK)
  • Abstract #4837 / 27 – Development of an in vitro 3D glioblastoma model system for patient-specific drug response profiling Tuesday,
    Apr 4, 2017 1:00 PM – 5:00 PM | Location: Section 39 / Poster 27 (LINK)
3D Cell Culture Models

3 Posters Accepted at AACR 2017 Washington DC


  • 0

KIYATEC & Mayo Clinic Collaborate to Fight Ovarian Cancer

Tags : 

KIYATEC AND MAYO CLINIC COLLABORATE TO FIGHT OVARIAN CANCER

Collaboration aims to validate the accuracy ex vivo 3D (EV3D) cell culture predictions against ovarian cancer patient outcomes

Greenville, S.C. | June 16, 2016 07:00 EDT – KIYATEC, a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced a collaboration with Mayo Clinic to combine their complementary technology platforms for ovarian cancer clinical care.

Mayo Clinic is actively enrolling patients in a clinical study led by principal investigator John Weroha, M.D., in which patient-derived xenografts (PDX) generate living tumor samples specific to each enrolled ovarian cancer patient. The study assesses whether those samples can help determine which chemotherapy is most effective to treat that individual ovarian cancer patient should they become platinum resistant. A limitation of any PDX model is that it typically takes six to nine months before data is produced.  For some patients that don’t respond at all to the initial treatment information is needed in just a few weeks, a challenge inherent to any clinical study of this sort – until now.

KIYATEC similarly uses living tumor samples specific to each ovarian cancer patient in its active research study with Greenville Health System (GHS), the first healthcare provider to partner with KIYATEC on this research.  The difference is that KIYATEC uses its 3D cell culture platform to generate patient specific drug response prediction data in just 7 days.  If the research collaboration is successful, KIYATEC’s technology would complement the Mayo approach and allow for more patients to be treated according to personalized drug response models.

 “This significantly advances KIYATEC’s goal to validate the accuracy of our cell culture predictions against patient outcomes, the gold standard for these kinds of comparisons,” said Hal Crosswell, M.D., KIYATEC’s Chief Medical Officer.

About KIYATEC

KIYATEC’s mission is to accurately predict patient response to cancer drugs using their living tumor cells in 3D culture, and to use those predictions to improve patient outcomes, reduce healthcare costs and increase success in drug development and clinical trials.  The company creates and utilizes live phenotypic 3D cell-based models for drug response profiling and applies them to generate information relevant to preclinical testing, clinical trials and clinical cancer diagnostic applications. 

For more information, please visit www.kiyatec.com or follow KIYATEC on Twitter (@KIYATEC).


  • 0

KIYATEC Announces Inaugural SAB Members

Tags : 

KIYATEC Announces Inaugural Scientific Advisory Board Members

Experts to Provide Invaluable Insight and Guidance to Advance Predictive Cancer Diagnostics.
Members:  Carlos L. Arteaga, MD (Vanderbilt University), David Kaplan, PhD (Tufts University), Anil Sood, MD (MD Anderson)

Greenville, S.C. | April 4, 2016 – KIYATEC, a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced the appointment of leading experts to its scientific advisory board (SAB).   The SAB will serve in a strategic oversight capacity to help guide KIYATEC as it continues the development and validation of predictive cancer diagnostics and complex ex vivo 3D tumor models.

“This is the ideal group to help us take a quantum leap forward for cancer patients and their treatment decisions” said Matt Gevaert, Ph.D., KIYATEC’s CEO. “The impressive scientific and clinical backgrounds of our SAB members bring a level of expertise rarely seen in the clinical diagnostics markets.  In conjunction with our exceptional scientific team at KIYATEC, our SAB will lead us towards developing the world’s most clinically relevant and predictive cancer diagnostics.”

The members of KIYATEC’s scientific advisory board include:

  • Carlos L. Arteaga, MD (Vanderbilt University) is the Donna S. Hall Chair in Breast Cancer Research and Professor of Medicine and Cancer Biology at Vanderbilt University. Dr. Arteaga is Director of the Center for Cancer Targeted Therapies and the Breast Cancer Program and Associate Director for Translational/Clinical Research at the Vanderbilt-Ingram Cancer Center (VICC). He is funded by the National Cancer Institute, the American Cancer Society, the Department of Defense Breast Cancer Research Program and Stand Up 2 Cancer (SU2C) among others.  He is an inducted member of the American Society of Clinical Investigation (1998) and the Association of American Physicians (2005).  Arteaga is a former recipient of the AACR Richard & Hinda Rosenthal Award, an ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO), the 2011 Brinker Award from the Susan G. Komen for the Cure Foundation, and the 2015 Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation. He was elected Fellow of the AACR Academy in 2015 and serves in the Scientific Advisory Board of the Komen Foundation. He served as the 2014-5 President of the American Association of Cancer Research (AACR).
  • David Kaplan, PhD (Tufts University) is the Stern Family Professor of Engineering, an Endowed Chair at Tufts University. He is also Professor and Chair of the Department of Biomedical Engineering there and also holds faculty appointments in the School of Medicine, the School of Dental Medicine, Department of Chemistry and the Department of Chemical and Biological Engineering. His research focus is on biopolymer engineering with emphasis on studies related to biomaterials engineering and functional tissue engineering/regenerative medicine. He has published over 600 peer reviewed papers and edited eight books. He directs the NIH P41 Tissue Engineering Resource Center (TERC) bridging Tufts University and Columbia University and is Associate Editor for the ACS journal Biomacromolecules. He has received a number of awards for teaching.   Kaplan is an Elected Fellow of the American Institute of Medical and Biological Engineering, has been honored with the Columbus Discovery Medal and Society for Biomaterials Clemson Award and serves of the editorial boards of numerous scientific journals.
  • Anil Sood, MD (MD Anderson) is the Vice Chair for Translational Research in the Departments of Gynecologic Oncology & Reproductive Medicine at MD Anderson, and is a Leader in Breast and Ovarian Cancers Moon Shot program focusing on triple-negative breast cancer (TNBC) and high-grade serous ovarian cancer (HGSOC). He is also Director of the Blanton-Davis Ovarian Cancer Research Program and Co-Director of the Center for RNA Interference and Non-Coding RNA.   Sood has received major recognition for his research accomplishments including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Prize for Outstanding Gynecologic Cancer Researcher.  He is an elected member of the American Society for Clinical Investigation and AAAS.

“The formation of KIYATEC’s SAB reflects our collective commitment to translate patient-derived tumor models into functional drug response assays and biomarkers,” said Hal Crosswell, MD, Chief Medical Officer of KIYATEC.  “We are honored to be working with such an esteemed and accomplished board who share our mission of improving lives of cancer patients.”

KIYATEC Cancer Diagnostics SAB


  • 0

3 KIYATEC Posters @AACR 2016

Tags : 

Three KIYATEC abstracts accepted for poster presentations during 2016 AACR Conference in New Orleans

KIYATEC, a private company prioritizing accurate ex vivo prediction of patients’ response to drug treatment, received acceptance of three posters for presentations during the upcoming AACR conference.

GREENVILLE, SC, March 21, 2016– KIYATEC Inc. is pleased to announce that three abstracts have been accepted by the committee at the American Association for Cancer Research (www.aacr.org).  KIYATEC scientific and business development staff will be in attendance at the conference.  In addition to the poster presentations, also KIYATEC will be exhibiting at Booth 1050.  Stop by to learn more about our 10+ years of 3D cell culture experience and the latest 3D co-culture model development projects focused on immuno-oncology applications.

  •  Abstract #611: A Complex 3D Model of Glioblastoma for Patient-Specific Drug Response Profiling  | Sunday Apr 17, 2016 1:00 PM – 5:00 PM | Location: Section 28 / Poster 12
  • Abstract #2531: Marker free isolation and expansion of cancer stem cells from small cell lung cancer | Monday, Apr 18, 2016, 1:00 PM – 5:00 PMLocation: Section 34 / Poster 20
  • Abstract # 5119: Complex, 3D tissues for modeling the immune response in cancer and predicting the activity of immunotherapies | Wednesday Apr 20, 2016 8:00 AM – 12:00 PM | Location: Section 31 / Poster 5

Ex Vivo 3D Cancer Models


  • 1

NIBIB Contract: 3D Bone Marrow Mimetic

Tags : 

National Institute of Biomedical Imaging and Bioengineering (NIBIB) Awards KIYATEC $225,000 to Develop 3D Platelet Bank 

Contract Funds 3D Microbioreactor Bone Marrow Mimetic for Platelet Production

GREENVILLE, SC | September 30, 2015 – KIYATEC announced today that it has been awarded a $225,000 Small Business Innovation Research (SBIR) Phase I Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH).  Over the course of the six month award, KIYATEC will develop 3D microbioreactors useful for the in vitro production of platelets and advance its technology around bone marrow models.  Bone marrow has important implications for the company’s focus in 3D cancer assays, especially with respect to immuno-oncology models combining cancer and the human immune system.  In collaboration with Tufts University’s biomaterial scaffold design and fabrication expertise, KIYATEC will develop a perfusion bioreactor system containing a live bone marrow mimetic capable of generating clinically relevant quantities of platelets from initial bone marrow precursor cells and then characterize their morphology and function.

3D Bone Marrow Mimetic


  • 0

KIYATEC 3DKUBE® Featured in Tufts Publication

Tags : 

KIYATEC 3DKUBE® FEATURED IN RECENT PUBLICATION IN 3D CELL CULTURE METHODS

The 3DKUBE® perfusion bioreactor from KIYATEC was recently featured in the article entitled “Long term perfusion system supporting adipogenesis”

GREENVILLE, SC | April 2, 2015 – KIYATEC Inc. is pleased to announce that our 3DKUBE® perfusion bioreactor system was used to enable long term, in vitro viability and adipogenesis by researchers at Tufts University.  The article highlights the key advantages of 3D perfusion cell culture versus standard 2D and perfused 2D cell culture methods in creating adipogenic cells from preadipocyte cultures.

The work was authored by Rosalyn D. Abbott et al and results from many years of research into 3D perfusion cell culture techniques in the labs of David Kaplan at Tufts University.  The article may be purchased online at: http://www.sciencedirect.com/science/article/pii/S1046202315001395

Key highlights of the research include:

• 2D and 3D perfusion culture techniques supported adipogenesis of preadipocytes.
• 3D perfusion contained adipocytes that were lost in the 2D perfused cultures.
• 3D perfusion stimulated greater lipogenesis and lipolysis compared to 2D perfusion.
• 3D perfusion stimulated decreased amounts of LDH compared to 2D perfusion.
• Greater glycerol was secreted with perfusion versus static cultures.


  • 0

$2M NCI Contract To Advance Predictive Cancer Diagnostics

Tags : 

National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics

Contract Funds 3D Breast Cancer, 3D Brain Cancer Micro-Tumor Development

GREENVILLE, SC | September 18, 2014 – KIYATEC announced today that it has been awarded a $1.975 million, Small Business Innovation Research (SBIR) Phase II Contract from the National Cancer Institute (NCI), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH). Over the course of the two year award, KIYATEC will expand its 3D breast cancer model to address two issues at the forefront of cancer therapy strategies: 1) cancer’s interaction with the patient’s immune system (immuno-oncology) and 2) cancer’s interaction with the patient’s blood supply (angiogenesis). The award will also allow KIYATEC to broaden its technology platform beyond its current use in primary ovarian cancer and breast cancer testing and into glioblastoma multiforme (GBM), a type of brain cancer with a five year survival rate that is less than 10 percent. The funded contract has the potential to radically change the future of cancer patient care.

Predictive 3D Cancer Diagnostics


x Shield Logo
This Site Is Protected By
The Shield →